<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vertical transmission of hepatitis C virus</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vertical transmission of hepatitis C virus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Vertical transmission of hepatitis C virus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric Goldberg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donough J O'Donovan, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth B Rand, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adrian M Di Bisceglie, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Worldwide, hepatitis B and C are the most common causes of chronic viral hepatitis in children and adults [<a href="#rid1">1</a>]. In industrialized nations, because of vaccination programs against hepatitis B, hepatitis C virus (HCV) has become the primary cause of chronic viral hepatitis in children [<a href="#rid2">2</a>], with vertical transmission becoming the leading source of infection [<a href="#rid3">3-5</a>]. Vertical transmission refers to viral transmission from the mother to the infant during pregnancy, at the time of delivery, or during the first 28 days after birth.</p><p>The issues surrounding vertical transmission of HCV are reviewed here. Discussion of the effects of pregnancy on HCV infection and HCV infection in children are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3561.html" rel="external">"Pregnancy in women with pre-existing chronic liver disease", section on 'Chronic hepatitis C virus'</a> and  <a class="medical medical_review" href="/z/d/html/5944.html" rel="external">"Hepatitis C virus infection in children"</a>.)</p><p class="headingAnchor" id="H68345571"><span class="h1">TIMING OF TRANSMISSION</span><span class="headingEndMark"> — </span>The mechanisms underlying vertical transmission of HCV are poorly understood. Intrauterine transmission during pregnancy and infection at the time of delivery are both possible, although it appears that the majority of HCV-infected infants are infected perinatally (either late intrauterine or intrapartum). </p><p>The timing of transmission can be reflected by results of polymerase chain reaction (PCR) testing for HCV RNA, which may not be positive until several weeks following infection, when levels of viremia reach the detection threshold. In most infants, HCV RNA levels only become detectable several weeks after birth, suggesting perinatal infection [<a href="#rid6">6-8</a>]. However, detection of HCV RNA within a few days of delivery has also been described, suggesting that in utero infection earlier in pregnancy can also occur.</p><p class="headingAnchor" id="H2"><span class="h1">INCIDENCE</span><span class="headingEndMark"> — </span>Vertical transmission of HCV has been documented in numerous studies, but estimates on the rate of transmission vary [<a href="#rid9">9-23</a>]. Some of the variability in estimates of may be the result of differences in study methodologies and maternal populations studied. Overall, it appears that the risk of vertical transmission is approximately five percent in viremic women, with higher rates in certain subgroups, namely women who are coinfected with HIV. (See <a class="local">'HIV coinfection'</a> below.). </p><p>One meta-analysis included 20 studies of pregnant women with chronic HCV infection (HCV antibody and RNA positive) that determined transmission by laboratory testing of the infant after at least 18 months of age [<a href="#rid24">24</a>]. The pooled transmission rate was 5.8 percent (95% CI 4.2-7.8) among women with HCV monoinfection and 10.8 percent (95% CI 7.6-15.2) among those with HCV/HIV coinfection. These results were generally consistent with a prior systematic review, in which the overall adjusted rate of vertical HCV transmission from anti-HCV antibody positive women was 1.7 percent, but 4.3 percent among HCV viremic women and up to 19.4 percent in HCV/HIV-coinfected women [<a href="#rid25">25</a>].</p><p>In the United States, given this risk of vertical transmission and the rising rates of HCV infection in women of childbearing age, the prevalence of HCV infection in children appears to be substantially underestimated. One study estimated that 29,000 women with HCV infection gave birth each year between 2011 and 2014 in the United States, which would translate to an estimated 1700 infants infected annually [<a href="#rid26">26</a>]. However, among children aged 2 to 13 years, only an average of 207 HCV infections were reported each year during that time period. Although advances in HCV treatment since the time of this study have the potential to reduce the burden of HCV infection among women of childbearing age, these data highlight the importance of identifying infected women and linking those with HCV infection to care. (See <a class="local">'Screening and prevention'</a> below and  <a class="medical medical_review" href="/z/d/html/5944.html" rel="external">"Hepatitis C virus infection in children", section on 'Epidemiology'</a>.) </p><p class="headingAnchor" id="H3"><span class="h1">ESTABLISHED RISK FACTORS FOR TRANSMISSION</span><span class="headingEndMark"> — </span>Several risk factors have been associated with an increased risk of vertical transmission. The most consistent associations have been with maternal HCV viremia during pregnancy or at the time of delivery and with concomitant HIV infection [<a href="#rid24">24,25</a>]. However, other variables, such as maternal intravenous drug use and peripheral blood mononuclear cell infection, also appear to increase the risk of transmission. </p><p class="headingAnchor" id="H4"><span class="h2">HCV viremia</span><span class="headingEndMark"> — </span>Vertical transmission is generally confined to women with detectable HCV RNA during pregnancy [<a href="#rid10">10,18,19,22,27-34</a>], though it has been reported in women without detectable HCV RNA [<a href="#rid18">18,27,31</a>]. This may have occurred because viremia can be intermittent, so a negative test earlier in pregnancy does not preclude viremia in the perinatal period. Mothers who have antibodies to HCV but are negative for HCV RNA virtually never transmit infection to their infants. </p><p>Most evidence supports an increased risk of transmission with higher HCV viral loads [<a href="#rid10">10,22,33-39</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 10 observational studies that included over 1300 newborns of mothers with HCV infection, the pooled transmission rate among mothers with a viral level ≥1 x 10<sup>6</sup> copies/mL was 9.6 percent, compared with 2.2 percent among mothers with a viral level &lt;1 x 10<sup>6</sup> copies/mL) [<a href="#rid34">34</a>]. </p><p></p><p>However, not all have found an association between the maternal viral load and vertical transmission [<a href="#rid19">19-21,40</a>]. As an example, in a study of 403 infants born to women with HCV, 13 infants (3 percent) acquired HCV [<a href="#rid19">19</a>]. The HCV RNA levels did not differ significantly between the women who transmitted the infection and those who did not (4 x 10<sup>5</sup> versus 2 x 10<sup>5</sup> copies/mL).</p><p class="headingAnchor" id="H5"><span class="h2">HIV coinfection</span><span class="headingEndMark"> — </span>Coinfection with HIV has been associated with a significantly increased risk of vertical transmission of HCV in numerous reports [<a href="#rid6">6,11,18,21,24,37,41,42</a>]. A systematic review that included 20 studies estimated that in women who had HIV coinfection, the risk of vertical transmission was increased approximately twofold compared with women who did not have HIV infection (10.8 versus 5.8 percent) [<a href="#rid24">24</a>].</p><p>The increased rate of vertical transmission in mothers with HIV coinfection may in part be explained by higher HCV RNA levels resulting from HIV-mediated immunosuppression [<a href="#rid11">11,43</a>]. For example, in one study, the average HCV RNA titers were approximately 10 times higher in women with HCV and HIV coinfection compared with women with HCV infection alone (7.8 x 10<sup>6</sup> versus 9 x 10<sup>5</sup> copies/mL) [<a href="#rid11">11</a>]. </p><p>The importance of HIV-mediated immunosuppression was suggested in a series of 155 children born to HCV RNA-positive mothers who were followed for at least 12 months [<a href="#rid40">40</a>]. Although 15 mothers had HIV coinfection, none transmitted HCV to their offspring. All of women with HIV coinfection were taking antiretroviral therapy, and their mean HCV RNA titer was similar to mothers without HIV coinfection. Thus, whether HIV is an independent risk factor for vertical transmission of HCV or whether HIV confers increased risk of vertical transmission simply because mothers with HIV coinfection have higher HCV titers is uncertain. (See  <a class="medical medical_review" href="/z/d/html/15799.html" rel="external">"Antiretroviral selection and management in pregnant individuals with HIV in resource-rich settings"</a>.)</p><p>Interestingly, infants of mothers with coinfection who acquire HIV infection have a greater risk of developing HCV infection compared with infants who do not acquire HIV infection (17 versus 5 percent in one series) [<a href="#rid37">37</a>]. Why this might occur is not clear. </p><p class="headingAnchor" id="H68346387"><span class="h2">Maternal intravenous drug use</span><span class="headingEndMark"> — </span>Women with a history of intravenous drug use have higher transmission rates of HCV to their infants than women without such a history [<a href="#rid15">15,16,18,44-47</a>]. In a study of 1372 HCV-positive women, a history of intravenous drug use was a significant predictor of HCV transmission to the infant (adjusted odds ratio 1.5; 95% confidence interval 1.2-1.9) [<a href="#rid47">47</a>]. The higher transmission rate may be related to an increased frequency of peripheral blood mononuclear cell infection in women with a history of intravenous drug use [<a href="#rid44">44,48</a>]. (See <a class="local">'Peripheral blood mononuclear cell infection'</a> below.)</p><p class="headingAnchor" id="H68345723"><span class="h2">Peripheral blood mononuclear cell infection</span><span class="headingEndMark"> — </span>Peripheral blood mononuclear cell (PBMC) infection is another factor associated with an increased risk of vertical transmission of HCV [<a href="#rid44">44,49</a>]. In a study of 48 mothers with HCV who transmitted the virus to their infants and 122 mothers with HCV who did not transmit the virus, PBMC infection was significantly more likely in mothers who transmitted the virus compared with mothers who did not (100 versus 54 percent). It has been hypothesized that PBMC infection may increase the risk of HCV transmission by serving as a vector for the HCV or because the viral variant of HCV that infects PBMCs is able to interact with and overcome the immune cells of the placenta [<a href="#rid44">44</a>]. </p><p class="headingAnchor" id="H68345885"><span class="h1">POSSIBLE RISK FACTORS FOR TRANSMISSION</span><span class="headingEndMark"> — </span>In addition to the established risk factors described above, other risk factors that are not as clearly established but that may increase the risk of vertical transmission of HCV included prolonged rupture of membranes and the performance of obstetric procedures.</p><p class="headingAnchor" id="H2715675347"><span class="h2">Invasive prenatal testing</span><span class="headingEndMark"> — </span>Invasive prenatal testing could theoretically increase the risk of transmission by increasing fetal exposure to maternal blood, although limited data have not suggested a clear risk with amniocentesis [<a href="#rid50">50</a>]. There are no data on the risk with chorionic villous sampling. In cases when invasive prenatal testing is indicated, amniocentesis is suggested over chorionic villus sampling [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/z/d/html/5390.html" rel="external">"Diagnostic amniocentesis", section on 'Vertical transmission'</a>.)</p><p class="headingAnchor" id="H68346417"><span class="h2">Prolonged rupture of membranes</span><span class="headingEndMark"> — </span>Avoiding prolonged rupture of membranes in HCV-infected women is recommended [<a href="#rid51">51</a>]. Rupture of membranes for six or more hours prior to delivery has been identified as a risk factor for transmission in several studies [<a href="#rid31">31,36,52,53</a>], though not all studies confirm the association [<a href="#rid54">54</a>]. In a study of 244 infants born to HCV-positive women, prolonged rupture of membranes was significantly associated with an increased risk of HCV transmission (adjusted odds ratio 9.3; 95% confidence interval 1.5-180) [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H68346425"><span class="h2">Obstetric procedures</span><span class="headingEndMark"> — </span>Invasive obstetric procedures, such as scalp electrode monitoring of the fetus during delivery, may increase the risk of HCV transmission by exposing the fetus to maternal blood. Obstetric management should minimize the duration of fetal exposure to maternal fluids and blood, and avoiding such invasive procedures is advised, although there are no data to demonstrate that doing so reduces transmission [<a href="#rid51">51,55</a>]. The possible risks of interventions during management of labor should be weighed against the obstetrical indications and benefits. (See  <a class="medical medical_review" href="/z/d/html/418.html" rel="external">"Intrapartum fetal heart rate monitoring: Overview"</a>.)</p><p>Data on the risk of such procedures are mixed. In a prospective study of 244 infants born to HCV-infected mothers, internal fetal monitoring was associated with an increased risk of transmission (odds ratio 6.7; 95% confidence interval 1.1-36) [<a href="#rid36">36</a>]. Fetal scalp monitoring was independently associated with HCV transmission in one [<a href="#rid56">56</a>] but not another retrospective study [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H68345893"><span class="h1">FACTORS NOT ASSOCIATED WITH TRANSMISSION</span></p><p class="headingAnchor" id="H153461426"><span class="h2">HCV genotype</span><span class="headingEndMark"> — </span>HCV genotype does not appear to be associated with vertical transmission. One series included 63 pregnant women with detectable HCV RNA, 20 of whom (32 percent) were coinfected with HIV [<a href="#rid16">16</a>]. Genotype 1 was most common (59 percent), followed by genotypes 2 (20.5 percent), 3 (19 percent), and 4 (1.5 percent). There was no difference in transmission rates between the mother who transmitted the virus and those who did not with regard to HCV genotype. Similar results were seen in a second study with 113 women, in whom the HIV infection rate was lower (12 percent) [<a href="#rid29">29</a>]. Among the 69 women with detectable HCV RNA, HCV genotype was not associated with perinatal HCV transmission.</p><p class="headingAnchor" id="H68345961"><span class="h2">Mode of delivery</span><span class="headingEndMark"> — </span>The mode of delivery does not appear to be associated with the risk of vertical transmission of HCV [<a href="#rid53">53</a>]. Theoretically, the mode of delivery may be important because exposure to HCV-infected blood as the infant passes through the birth canal could lead to HCV transmission. However, exposure to maternal blood can also occur with cesarean delivery. Currently, pregnant women infected with HCV are <strong>not</strong> advised to have cesarean delivery, unless indicated for other reasons [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/z/d/html/4475.html" rel="external">"Cesarean birth: Preoperative planning and patient preparation", section on 'Indications'</a>.)</p><p>Among women who are not infected with HIV, the mode of delivery does not appear to influence transmission rates. In a meta-analysis that included eight studies with 641 mother-infant pairs, there was no significant difference in HCV transmission among HIV-negative women who had a cesarean delivery and those who had a vaginal delivery [<a href="#rid58">58</a>].</p><p>However, among HIV-positive women, some older studies suggest cesarean delivery may decrease the risk of HCV transmission. In study of 1419 women with HCV, 503 (35 percent) were coinfected with HIV [<a href="#rid42">42</a>]. HCV infection was seen in 70 of the infants born to HIV-positive women (14 percent) and in 60 of the infants born to HIV-negative women (7 percent). Among the women with HIV for whom delivery information was available, 159 (33 percent) had a cesarean delivery and 329 (67 percent) had a vaginal delivery. On multivariable analysis, HCV transmission was significantly less likely to occur with cesarean delivery (odds ratio 0.4). </p><p>However, with widespread use of antiretroviral therapy for HIV, the benefit of cesarean delivery may no longer exist. In a subsequent study with 1479 mother-infant pairs, there was no benefit from cesarean delivery for women coinfected with HCV and HIV [<a href="#rid31">31</a>]. In that study, 83 percent of women who were coinfected with HIV received antiretroviral treatment for their HIV. Thus, recommendations regarding the mode of delivery in women who are coinfected with HIV depend upon the status of the patient's HIV infection at the time of delivery. (See  <a class="medical medical_review" href="/z/d/html/13972.html" rel="external">"Prenatal evaluation of women with HIV in resource-rich settings", section on 'Viral load measurement'</a>.)</p><p class="headingAnchor" id="H68346108"><span class="h2">Breastfeeding</span><span class="headingEndMark"> — </span>The available evidence suggests that breastfeeding by an HCV-infected mother does not appreciably increase the risk of transmitting HCV to her offspring. Multiple expert groups all support breastfeeding by HCV-infected mothers, although they suggest that women abstain from breastfeeding if their nipples are cracked or bleeding [<a href="#rid51">51,55,59-61</a>]. The situation is more complex in women who are coinfected with HIV and HCV, in whom the risk of HIV transmission also is an issue. (See  <a class="medical medical_review" href="/z/d/html/13970.html" rel="external">"Prevention of HIV transmission during breastfeeding in resource-limited settings"</a>.)</p><p>HCV RNA is detectable in maternal colostrum [<a href="#rid62">62</a>]. However, acquisition of HCV via breastfeeding has not been documented. In one study, for example, none of the 76 samples of breast milk from 73 HCV antibody-positive (60 percent HCV RNA positive) mothers contained HCV RNA [<a href="#rid63">63</a>]. Only one of the 76 breast-fed infants had evidence of HCV infection by PCR; this infant's HCV infection was detected one month after birth, indicating that transmission via breast milk was unlikely. (See <a class="local">'Timing of transmission'</a> above.)</p><p>Other studies evaluating the effect of breastfeeding on HCV transmission concur with these findings [<a href="#rid53">53</a>]; either similar rates of infection are observed in breast-fed and bottle-fed groups, or no viral transmission was documented [<a href="#rid19">19,64,65</a>]. Breast milk itself may inhibit HCV infectivity. This was suggested by an in vitro study in which incubation in pre-frozen breast milk from uninfected donors, but not infant formula or milk from other species, reduced the infectivity of an experimental virus in a cell culture system, possibly through disruption of the viral envelope [<a href="#rid66">66</a>]. Other potential explanations as to why breast milk containing HCV RNA does not infect infants include inactivation of the virus by the acidity of the stomach and very low levels of HCV RNA in breast milk.</p><p class="headingAnchor" id="H160622615"><span class="h2">IL28B genotype</span><span class="headingEndMark"> — </span>IL28B genotype is an important predictor of clearance versus persistence of HCV infection. However, it does not appear to be associated with the risk of vertical transmission [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/3672.html" rel="external">"Clinical manifestations and natural history of chronic hepatitis C virus infection"</a>.)</p><p class="headingAnchor" id="H18554145"><span class="h1">SCREENING AND PREVENTION</span><span class="headingEndMark"> — </span>The main strategy for reducing the risk of vertical HCV transmission is identifying and treating individuals with HCV infection prior to conception [<a href="#rid55">55,67</a>]. </p><p>We agree with recommendations from the United States Centers for Disease Control and Prevention (CDC) to screening all pregnant women for HCV infection during each pregnancy [<a href="#rid68">68</a>]. </p><p>Improved identification of HCV infection during pregnancy can improve risk stratification to inform intrapartum management; for example, it is prudent to avoid prolonged rupture of membranes and invasive obstetric procedures in the setting of HCV because of the possible risk of transmission (see <a class="local">'Possible risk factors for transmission'</a> above). </p><p>Additionally, identifying pregnant individuals with HCV infection can facilitate appropriate follow-up for at-risk infants. Issues related to HCV screening are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection"</a> and  <a class="medical medical_review" href="/z/d/html/446.html" rel="external">"Prenatal care: Initial assessment", section on 'Hepatitis C'</a>.)</p><p class="headingAnchor" id="H552655431"><span class="h1">EVALUATION AND MANAGEMENT OF HCV IN PREGNANCY</span><span class="headingEndMark"> — </span>Evaluation of pregnant individuals with HCV is generally similar to that for HCV in general, and includes assessment of the HCV RNA level and the stage of liver disease. Antiviral therapy during pregnancy is not an option since the safety and efficacy of direct-acting antiviral agents in pregnancy have not been evaluated (and they should thus not be used in pregnant patients). Further studies are needed to assess these issues and inform the potential role of these antiviral agents to treat maternal HCV infection and prevent transmission to the infant.</p><p>As discussed above, procedures that are potential transmission risks should be minimized, if possible. (See <a class="local">'Possible risk factors for transmission'</a> above.)</p><p>HCV monoinfection does not impact delivery route. Postpartum, women with HCV infection (without HIV infection) can breastfeed, but should abstain from breastfeeding when their nipples are cracked or bleeding. (See <a class="local">'Factors not associated with transmission'</a> above.)</p><p>The treatment of HCV in nonpregnant adults is discussed in detail elsewhere. Of note, females who were treated with a ribavirin-containing regimen should avoid pregnancy for at least nine months afterwards. (See  <a class="medical medical_review" href="/z/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection"</a> and  <a class="medical medical_review" href="/z/d/html/16592.html" rel="external">"Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults"</a> and  <a class="medical medical_review" href="/z/d/html/15795.html" rel="external">"Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults"</a>.)</p><p class="headingAnchor" id="H3586404018"><span class="h1">HCV IN INFANTS</span></p><p class="headingAnchor" id="H3545390587"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>Newborn infants with HCV infection are usually asymptomatic, and a substantial proportion have normal or only mildly elevated serum alanine aminotransferase (ALT) concentrations [<a href="#rid27">27,69,70</a>]. In one study, for example, 104 infants with vertically acquired HCV infection were followed from birth for a mean of 49 months [<a href="#rid27">27</a>]. Although at least 90 percent of the infants had evidence of ongoing infection (based upon polymerase chain reaction [PCR] analysis for the detection of HCV RNA), clinical manifestations were rare. None of the infants had significant growth failure. Most had transient or persistent increases in serum ALT concentrations. The serum ALT usually was only mildly elevated or normal at birth, increasing at four to six months of age. Levels remained elevated for two years and declined substantially thereafter in most infants.</p><p>Twenty infants underwent liver biopsy. Although no single typical histologic feature was observed, all had histologic evidence of minimal to moderate chronic hepatitis, and three had some degree of fibrosis. Similar findings were reported in other studies [<a href="#rid69">69-71</a>]. Overall, the data suggest that vertically acquired HCV infection is usually asymptomatic during infancy but often is associated with elevation of ALT concentrations during the first 6 to 12 months of life.</p><p>Although progression to chronicity occurs in most infants with vertically acquired HCV, liver disease usually is mild throughout childhood. (See  <a class="medical medical_review" href="/z/d/html/5944.html" rel="external">"Hepatitis C virus infection in children", section on 'Natural history'</a>.)</p><p>One of the largest series with long-term follow-up of children with perinatally acquired HCV included 266 children who were followed for a median of 4.2 years [<a href="#rid72">72</a>]. Approximately 20 percent cleared the infection at a median age of 15 months, whereas 80 percent had chronic infection. Clearance was less likely in children who were persistently PCR positive during the first year of life and in those who remained PCR positive after the first year of life. Most children with chronic infection were asymptomatic. </p><p>Additional long-term follow-up studies are necessary to determine what proportion of infants with vertically acquired HCV will develop hepatic failure or hepatocellular carcinoma. </p><p class="headingAnchor" id="H3328315107"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Approach to diagnosis of HCV in infants is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5944.html" rel="external">"Hepatitis C virus infection in children", section on 'How to test'</a>.)</p><p class="headingAnchor" id="H3415493318"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113060.html" rel="external">"Society guideline links: Hepatitis C virus infection"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence</strong> – Vertical transmission of hepatitis C virus (HCV) occurs exclusively among women with detectable HCV RNA in the blood. The transmission rate is approximately 5 percent among HCV-monoinfected women and approximately 10 percent among HCV/HIV-coinfected women. (See <a class="local">'Incidence'</a> above and <a class="local">'HIV coinfection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – In addition to HIV coinfection, other risk factors for transmission include high HCV viral load, a history of intravenous drug use, and HCV infection of peripheral blood mononuclear cells. Prolonged rupture of membranes and the performance of obstetric procedures such as fetal scalp monitoring may also be associated with vertical transmission. When possible, obstetric procedures should be avoided in women with HCV. (See <a class="local">'Established risk factors for transmission'</a> above and <a class="local">'Possible risk factors for transmission'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factors not associated with vertical transmission</strong> – These include viral genotype, the mode of delivery (in women without HIV or in women with HIV who are taking antiretroviral therapy), and breastfeeding. Pregnant women with HCV are <strong>not</strong> advised to have cesarean delivery, unless indicated for other reasons. (See <a class="local">'Factors not associated with transmission'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening and prevention</strong> – The main strategy for reducing the risk of vertical HCV transmission is identifying and treating HCV-infected women prior to conception. Screening is also suggested for all pregnant women during each pregnancy to help inform intrapartum care and identify infants who warrant follow-up. Issues related to HCV screening are discussed further separately. (See <a class="local">'Screening and prevention'</a> above and  <a class="medical medical_review" href="/z/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection"</a> and  <a class="medical medical_review" href="/z/d/html/446.html" rel="external">"Prenatal care: Initial assessment", section on 'Hepatitis C'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No antiviral therapy during pregnancy</strong> – The safety and efficacy of direct-acting antiviral agents during pregnancy and in neonates have not yet been assessed, and these agents should not be used in such populations. The treatment of HCV in children is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5944.html" rel="external">"Hepatitis C virus infection in children", section on 'Management of chronic hepatitis C virus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HCV in infants</strong> – Infants who acquire HCV perinatally are typically asymptomatic, although an elevated alanine aminotransferase level is common. Diagnosis of HCV in infants is discussed in detail elsewhere. (See <a class="local">'Clinical manifestations'</a> above and  <a class="medical medical_review" href="/z/d/html/5944.html" rel="external">"Hepatitis C virus infection in children", section on 'How to test'</a>.)</p><p></p><p class="headingAnchor" id="H2845569549"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Sanjiv Chopra, MD, MACP, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Williams R. Global challenges in liver disease. Hepatology 2006; 44:521.</a></li><li><a class="nounderline abstract_t">Slowik MK, Jhaveri R. Hepatitis B and C viruses in infants and young children. Semin Pediatr Infect Dis 2005; 16:296.</a></li><li><a class="nounderline abstract_t">Bortolotti F, Resti M, Giacchino R, et al. Changing epidemiologic pattern of chronic hepatitis C virus infection in Italian children. J Pediatr 1998; 133:378.</a></li><li><a class="nounderline abstract_t">Bortolotti F, Iorio R, Resti M, et al. An epidemiological survey of hepatitis C virus infection in Italian children in the decade 1990-1999. J Pediatr Gastroenterol Nutr 2001; 32:562.</a></li><li><a class="nounderline abstract_t">Bortolotti F, Iorio R, Resti M, et al. Epidemiological profile of 806 Italian children with hepatitis C virus infection over a 15-year period. J Hepatol 2007; 46:783.</a></li><li><a class="nounderline abstract_t">Gibb DM, Goodall RL, Dunn DT, et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 2000; 356:904.</a></li><li><a class="nounderline abstract_t">Mok J, Pembrey L, Tovo PA, et al. When does mother to child transmission of hepatitis C virus occur? Arch Dis Child Fetal Neonatal Ed 2005; 90:F156.</a></li><li><a class="nounderline abstract_t">Polywka S, Pembrey L, Tovo PA, Newell ML. Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection. J Med Virol 2006; 78:305.</a></li><li><a class="nounderline abstract_t">Thaler MM, Park CK, Landers DV, et al. Vertical transmission of hepatitis C virus. Lancet 1991; 338:17.</a></li><li><a class="nounderline abstract_t">Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994; 330:744.</a></li><li><a class="nounderline abstract_t">Zanetti AR, Tanzi E, Paccagnini S, et al. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet 1995; 345:289.</a></li><li><a class="nounderline abstract_t">Reinus JF, Leikin EL, Alter HJ, et al. Failure to detect vertical transmission of hepatitis C virus. Ann Intern Med 1992; 117:881.</a></li><li><a class="nounderline abstract_t">Kuroki T, Nishiguchi S, Fukuda K, et al. Vertical transmission of hepatitis C virus (HCV) detected by HCV-RNA analysis. Gut 1993; 34:S52.</a></li><li><a class="nounderline abstract_t">Matsubara T, Sumazaki R, Takita H. Mother-to-infant transmission of hepatitis C virus: a prospective study. Eur J Pediatr 1995; 154:973.</a></li><li><a class="nounderline abstract_t">Sabatino G, Ramenghi LA, di Marzio M, Pizzigallo E. Vertical transmission of hepatitis C virus: an epidemiological study on 2,980 pregnant women in Italy. Eur J Epidemiol 1996; 12:443.</a></li><li><a class="nounderline abstract_t">Mazza C, Ravaggi A, Rodella A, et al. Prospective study of mother-to-infant transmission of hepatitis C virus (HCV) infection. Study Group for Vertical Transmission. J Med Virol 1998; 54:12.</a></li><li><a class="nounderline abstract_t">Giacchino R, Tasso L, Timitilli A, et al. Vertical transmission of hepatitis C virus infection: usefulness of viremia detection in HIV-seronegative hepatitis C virus-seropositive mothers. J Pediatr 1998; 132:167.</a></li><li><a class="nounderline abstract_t">Granovsky MO, Minkoff HL, Tess BH, et al. Hepatitis C virus infection in the mothers and infants cohort study. Pediatrics 1998; 102:355.</a></li><li><a class="nounderline abstract_t">Resti M, Azzari C, Mannelli F, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. BMJ 1998; 317:437.</a></li><li><a class="nounderline abstract_t">Manzini P, Saracco G, Cerchier A, et al. Human immunodeficiency virus infection as risk factor for mother-to-child hepatitis C virus transmission; persistence of anti-hepatitis C virus in children is associated with the mother's anti-hepatitis C virus immunoblotting pattern. Hepatology 1995; 21:328.</a></li><li><a class="nounderline abstract_t">Paccagnini S, Principi N, Massironi E, et al. Perinatal transmission and manifestation of hepatitis C virus infection in a high risk population. Pediatr Infect Dis J 1995; 14:195.</a></li><li><a class="nounderline abstract_t">Moriya T, Sasaki F, Mizui M, et al. Transmission of hepatitis C virus from mothers to infants: its frequency and risk factors revisited. Biomed Pharmacother 1995; 49:59.</a></li><li><a class="nounderline abstract_t">Zuccotti GV, Ribero ML, Giovannini M, et al. Effect of hepatitis C genotype on mother-to-infant transmission of virus. J Pediatr 1995; 127:278.</a></li><li><a class="nounderline abstract_t">Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis 2014; 59:765.</a></li><li><a class="nounderline abstract_t">Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001; 34:223.</a></li><li><a class="nounderline abstract_t">Ly KN, Jiles RB, Teshale EH, et al. Hepatitis C Virus Infection Among Reproductive-Aged Women and Children in the United States, 2006 to 2014. Ann Intern Med 2017; 166:775.</a></li><li><a class="nounderline abstract_t">Tovo PA, Pembrey LJ, Newell ML. Persistence rate and progression of vertically acquired hepatitis C infection. European Paediatric Hepatitis C Virus Infection. J Infect Dis 2000; 181:419.</a></li><li><a class="nounderline abstract_t">Dore GJ, Kaldor JM, McCaughan GW. Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. BMJ 1997; 315:333.</a></li><li><a class="nounderline abstract_t">Dal Molin G, D'Agaro P, Ansaldi F, et al. Mother-to-infant transmission of hepatitis C virus: rate of infection and assessment of viral load and IgM anti-HCV as risk factors. J Med Virol 2002; 67:137.</a></li><li><a class="nounderline abstract_t">Saez A, Losa M, Lo Iacono O, et al. Diagnostic and prognostic value of virologic tests in vertical transmission of hepatitis C virus infection: results of a large prospective study in pregnant women. Hepatogastroenterology 2004; 51:1104.</a></li><li><a class="nounderline abstract_t">European Paediatric Hepatitis C Virus Network. A significant sex--but not elective cesarean section--effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis 2005; 192:1872.</a></li><li><a class="nounderline abstract_t">Okamoto M, Nagata I, Murakami J, et al. Prospective reevaluation of risk factors in mother-to-child transmission of hepatitis C virus: high virus load, vaginal delivery, and negative anti-NS4 antibody. J Infect Dis 2000; 182:1511.</a></li><li><a class="nounderline abstract_t">Ceci O, Margiotta M, Marello F, et al. Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study. J Pediatr Gastroenterol Nutr 2001; 33:570.</a></li><li><a class="nounderline abstract_t">Deng S, Zhong W, Chen W, Wang Z. Hepatitis C viral load and mother-to-child transmission: A systematic review and meta-analysis. J Gastroenterol Hepatol 2023; 38:177.</a></li><li><a class="nounderline abstract_t">Lin HH, Kao JH, Hsu HY, et al. Possible role of high-titer maternal viremia in perinatal transmission of hepatitis C virus. J Infect Dis 1994; 169:638.</a></li><li><a class="nounderline abstract_t">Mast EE, Hwang LY, Seto DS, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005; 192:1880.</a></li><li><a class="nounderline abstract_t">Thomas DL, Villano SA, Riester KA, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis 1998; 177:1480.</a></li><li><a class="nounderline abstract_t">Ruiz-Extremera A, Muñoz-Gámez JA, Salmerón-Ruiz MA, et al. Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology 2011; 53:1830.</a></li><li><a class="nounderline abstract_t">Kushner T, Djerboua M, Biondi MJ, et al. Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission. J Hepatol 2022; 77:1256.</a></li><li><a class="nounderline abstract_t">Conte D, Fraquelli M, Prati D, et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 2000; 31:751.</a></li><li><a class="nounderline abstract_t">Tovo PA, Palomba E, Ferraris G, et al. Increased risk of maternal-infant hepatitis C virus transmission for women coinfected with human immunodeficiency virus type 1. Italian Study Group for HCV Infection in Children. Clin Infect Dis 1997; 25:1121.</a></li><li><a class="nounderline abstract_t">European Paediatric Hepatitis C Virus Network.. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. European Paediatric Hepatitis C Virus Network. BJOG 2001; 108:371.</a></li><li><a class="nounderline abstract_t">Ngo-Giang-Huong N, Jourdain G, Sirirungsi W, et al. Human immunodeficiency virus-hepatitis C virus co-infection in pregnant women and perinatal transmission to infants in Thailand. Int J Infect Dis 2010; 14:e602.</a></li><li><a class="nounderline abstract_t">Azzari C, Moriondo M, Indolfi G, et al. Higher risk of hepatitis C virus perinatal transmission from drug user mothers is mediated by peripheral blood mononuclear cell infection. J Med Virol 2008; 80:65.</a></li><li><a class="nounderline abstract_t">Zanetti AR, Tanzi E, Romanò L, et al. A prospective study on mother-to-infant transmission of hepatitis C virus. Intervirology 1998; 41:208.</a></li><li><a class="nounderline abstract_t">Resti M, Azzari C, Lega L, et al. Mother-to-infant transmission of hepatitis C virus. Acta Paediatr 1995; 84:251.</a></li><li><a class="nounderline abstract_t">Resti M, Azzari C, Galli L, et al. Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs. J Infect Dis 2002; 185:567.</a></li><li><a class="nounderline abstract_t">Resti M, Azzari C, Moriondo M, et al. Injection drug use facilitates hepatitis C virus infection of peripheral blood mononuclear cells. Clin Infect Dis 2002; 35:236.</a></li><li><a class="nounderline abstract_t">Azzari C, Resti M, Moriondo M, et al. Vertical transmission of HCV is related to maternal peripheral blood mononuclear cell infection. Blood 2000; 96:2045.</a></li><li><a class="nounderline abstract_t">Gagnon A, Davies G, Wilson RD, GENETICS COMMITTEE. RETIRED: Prenatal invasive procedures in women with hepatitis B, hepatitis C, and/or human immunodeficiency virus infections. J Obstet Gynaecol Can 2014; 36:648.</a></li><li><a class="nounderline abstract_t">Society for Maternal-Fetal Medicine (SMFM). Electronic address: <span class="__cf_email__" data-cfemail="235356415063504e454e0d4c5144">[email protected]</span>, Hughes BL, Page CM, Kuller JA. Hepatitis C in pregnancy: screening, treatment, and management. Am J Obstet Gynecol 2017; 217:B2.</a></li><li><a class="nounderline abstract_t">Spencer JD, Latt N, Beeby PJ, et al. Transmission of hepatitis C virus to infants of human immunodeficiency virus-negative intravenous drug-using mothers: rate of infection and assessment of risk factors for transmission. J Viral Hepat 1997; 4:395.</a></li><li><a class="nounderline abstract_t">Cottrell EB, Chou R, Wasson N, et al. Reducing risk for mother-to-infant transmission of hepatitis C virus: A systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2012; 158:109.</a></li><li><a class="nounderline abstract_t">Healy CM, Cafferkey MT, Conroy A, et al. Outcome of infants born to hepatitis C infected women. Ir J Med Sci 2001; 170:103.</a></li><li class="breakAll">AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. www.hcvguidelines.org (Accessed on September 21, 2017).</li><li><a class="nounderline abstract_t">Garcia-Tejedor A, Maiques-Montesinos V, Diago-Almela VJ, et al. Risk factors for vertical transmission of hepatitis C virus: a single center experience with 710 HCV-infected mothers. Eur J Obstet Gynecol Reprod Biol 2015; 194:173.</a></li><li><a class="nounderline abstract_t">McIntyre PG, Tosh K, McGuire W. Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission. Cochrane Database Syst Rev 2006; :CD005546.</a></li><li><a class="nounderline abstract_t">Ghamar Chehreh ME, Tabatabaei SV, Khazanehdari S, Alavian SM. Effect of cesarean section on the risk of perinatal transmission of hepatitis C virus from HCV-RNA+/HIV- mothers: a meta-analysis. Arch Gynecol Obstet 2011; 283:255.</a></li><li><a class="nounderline abstract_t">ACOG committee opinion. Breastfeeding and the risk of hepatitis C virus transmission. Number 220, August 1999. Committee on Obstetric Practice. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 1999; 66:307.</a></li><li><a class="nounderline abstract_t">Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47:1.</a></li><li class="breakAll">Recommendations for Testing, Managing, and Treating Hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. http://www.hcvguidelines.org/ (Accessed on May 24, 2018).</li><li><a class="nounderline abstract_t">Lin HH, Kao JH, Hsu HY, et al. Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers. J Pediatr 1995; 126:589.</a></li><li><a class="nounderline abstract_t">Polywka S, Schröter M, Feucht HH, et al. Low risk of vertical transmission of hepatitis C virus by breast milk. Clin Infect Dis 1999; 29:1327.</a></li><li><a class="nounderline abstract_t">Thomas SL, Newell ML, Peckham CS, et al. A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. Int J Epidemiol 1998; 27:108.</a></li><li><a class="nounderline abstract_t">Kumar RM, Shahul S. Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers. J Hepatol 1998; 29:191.</a></li><li><a class="nounderline abstract_t">Pfaender S, Heyden J, Friesland M, et al. Inactivation of hepatitis C virus infectivity by human breast milk. J Infect Dis 2013; 208:1943.</a></li><li><a class="nounderline abstract_t">Jack BW, Atrash H, Coonrod DV, et al. The clinical content of preconception care: an overview and preparation of this supplement. Am J Obstet Gynecol 2008; 199:S266.</a></li><li><a class="nounderline abstract_t">Schillie S, Wester C, Osborne M, et al. CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020. MMWR Recomm Rep 2020; 69:1.</a></li><li><a class="nounderline abstract_t">Bortolotti F, Resti M, Giacchino R, et al. Hepatitis C virus infection and related liver disease in children of mothers with antibodies to the virus. J Pediatr 1997; 130:990.</a></li><li><a class="nounderline abstract_t">Palomba E, Manzini P, Fiammengo P, et al. Natural history of perinatal hepatitis C virus infection. Clin Infect Dis 1996; 23:47.</a></li><li><a class="nounderline abstract_t">Mohan P, Colvin C, Glymph C, et al. Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J Pediatr 2007; 150:168.</a></li><li><a class="nounderline abstract_t">European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis 2005; 41:45.</a></li></ol></div><div id="topicVersionRevision">Topic 3637 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16941687" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Global challenges in liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16210109" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hepatitis B and C viruses in infants and young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9738720" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Changing epidemiologic pattern of chronic hepatitis C virus infection in Italian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11429517" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : An epidemiological survey of hepatitis C virus infection in Italian children in the decade 1990-1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17321633" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Epidemiological profile of 806 Italian children with hepatitis C virus infection over a 15-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11036896" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15724041" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : When does mother to child transmission of hepatitis C virus occur?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16372293" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1676085" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Vertical transmission of hepatitis C virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8107740" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7530793" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1332561" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Failure to detect vertical transmission of hepatitis C virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8390956" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Vertical transmission of hepatitis C virus (HCV) detected by HCV-RNA analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8801105" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Mother-to-infant transmission of hepatitis C virus: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8905303" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Vertical transmission of hepatitis C virus: an epidemiological study on 2,980 pregnant women in Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9443104" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prospective study of mother-to-infant transmission of hepatitis C virus (HCV) infection. Study Group for Vertical Transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9470023" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Vertical transmission of hepatitis C virus infection: usefulness of viremia detection in HIV-seronegative hepatitis C virus-seropositive mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9685438" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hepatitis C virus infection in the mothers and infants cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9703524" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7843701" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Human immunodeficiency virus infection as risk factor for mother-to-child hepatitis C virus transmission; persistence of anti-hepatitis C virus in children is associated with the mother's anti-hepatitis C virus immunoblotting pattern.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7761184" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Perinatal transmission and manifestation of hepatitis C virus infection in a high risk population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7605903" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Transmission of hepatitis C virus from mothers to infants: its frequency and risk factors revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7636656" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effect of hepatitis C genotype on mother-to-infant transmission of virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24928290" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Vertical transmission of hepatitis C virus: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11481604" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mother-to-infant transmission of hepatitis C virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28492929" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hepatitis C Virus Infection Among Reproductive-Aged Women and Children in the United States, 2006 to 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10669321" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Persistence rate and progression of vertically acquired hepatitis C infection. European Paediatric Hepatitis C Virus Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9270453" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11992574" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mother-to-infant transmission of hepatitis C virus: rate of infection and assessment of viral load and IgM anti-HCV as risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15239255" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Diagnostic and prognostic value of virologic tests in vertical transmission of hepatitis C virus infection: results of a large prospective study in pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16267757" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A significant sex--but not elective cesarean section--effect on mother-to-child transmission of hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11023474" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prospective reevaluation of risk factors in mother-to-child transmission of hepatitis C virus: high virus load, vaginal delivery, and negative anti-NS4 antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11740231" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36066543" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hepatitis C viral load and mother-to-child transmission: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8158040" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Possible role of high-titer maternal viremia in perinatal transmission of hepatitis C virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16267758" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9607823" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21413051" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35643203" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10706568" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9402369" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Increased risk of maternal-infant hepatitis C virus transmission for women coinfected with human immunodeficiency virus type 1. Italian Study Group for HCV Infection in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11305543" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. European Paediatric Hepatitis C Virus Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20047847" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Human immunodeficiency virus-hepatitis C virus co-infection in pregnant women and perinatal transmission to infants in Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18041020" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Higher risk of hepatitis C virus perinatal transmission from drug user mothers is mediated by peripheral blood mononuclear cell infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10213898" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A prospective study on mother-to-infant transmission of hepatitis C virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7540080" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mother-to-infant transmission of hepatitis C virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11865412" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12115087" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Injection drug use facilitates hepatitis C virus infection of peripheral blood mononuclear cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10979945" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Vertical transmission of HCV is related to maternal peripheral blood mononuclear cell infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25184985" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : RETIRED: Prenatal invasive procedures in women with hepatitis B, hepatitis C, and/or human immunodeficiency virus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28782502" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Hepatitis C in pregnancy: screening, treatment, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9430360" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Transmission of hepatitis C virus to infants of human immunodeficiency virus-negative intravenous drug-using mothers: rate of infection and assessment of risk factors for transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23437438" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Reducing risk for mother-to-infant transmission of hepatitis C virus: A systematic review for the U.S. Preventive Services Task Force</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11491043" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Outcome of infants born to hepatitis C infected women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11491043" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Outcome of infants born to hepatitis C infected women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26409061" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Risk factors for vertical transmission of hepatitis C virus: a single center experience with 710 HCV-infected mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17054264" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20652289" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effect of cesarean section on the risk of perinatal transmission of hepatitis C virus from HCV-RNA+/HIV- mothers: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10580686" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : ACOG committee opinion. Breastfeeding and the risk of hepatitis C virus transmission. Number 220, August 1999. Committee on Obstetric Practice. American College of Obstetricians and Gynecologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9790221" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9790221" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7535353" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10524987" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Low risk of vertical transmission of hepatitis C virus by breast milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9563703" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9722199" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24068703" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Inactivation of hepatitis C virus infectivity by human breast milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19081421" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The clinical content of preconception care: an overview and preparation of this supplement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32271723" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9202625" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Hepatitis C virus infection and related liver disease in children of mothers with antibodies to the virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8816128" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Natural history of perinatal hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17236895" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Clinical spectrum and histopathologic features of chronic hepatitis C infection in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15937762" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Three broad modalities in the natural history of vertically acquired hepatitis C virus infection.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
